Synonym
AMG-579; J3.339.633C; AMG 579; AMG579;
IUPAC/Chemical Name
1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethan-1-one
InChi Key
ZNPDAYJZIRPRFQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H23N5O3/c1-16(31)30-14-10-17(11-15-30)22-25(27-13-12-26-22)33-19-8-6-18(7-9-19)23(32)24-28-20-4-2-3-5-21(20)29-24/h2-9,12-13,17H,10-11,14-15H2,1H3,(H,28,29)
SMILES Code
O=C(C1=CC=C(OC2=NC=CN=C2C3CCN(C(C)=O)CC3)C=C1)C4=NC5=CC=CC=C5N4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
441.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Hruszkewycz DP, Miles KC, Thiel OR, Stahl SS. Co/NHPI-mediated aerobic oxygenation of benzylic C-H bonds in pharmaceutically relevant molecules. Chem Sci. 2017 Feb 1;8(2):1282-1287. doi: 10.1039/c6sc03831j. Epub 2016 Oct 7. PubMed PMID: 28451270; PubMed Central PMCID: PMC5359875.
2: Wu Q, Kennedy MT, Nagapudi K, Kiang YH. Humidity induced phase transformation of poloxamer 188 and its effect on physical stability of amorphous solid dispersion of AMG 579, a PDE10A inhibitor. Int J Pharm. 2017 Apr 15;521(1-2):1-7. doi: 10.1016/j.ijpharm.2017.01.059. Epub 2017 Feb 2. PubMed PMID: 28163226.
3: Wilson SF, Kerr SJ, Rose MJ, James CA. Validation of a method for the determination of AMG 579 in cerebrospinal fluid with a focus on sample collection procedures for clinical trials. J Pharm Biomed Anal. 2015 Apr 10;108:49-55. doi: 10.1016/j.jpba.2015.01.055. Epub 2015 Feb 7. PubMed PMID: 25706859.
4: Hu E, Chen N, Bourbeau MP, Harrington PE, Biswas K, Kunz RK, Andrews KL, Chmait S, Zhao X, Davis C, Ma J, Shi J, Lester-Zeiner D, Danao J, Able J, Cueva M, Talreja S, Kornecook T, Chen H, Porter A, Hungate R, Treanor J, Allen JR. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)e thanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41. doi: 10.1021/jm500713j. Epub 2014 Aug 4. PubMed PMID: 25062128.
